Filing Details
- Accession Number:
- 0001179110-21-010820
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-10 16:03:18
- Reporting Period:
- 2021-12-08
- Accepted Time:
- 2021-12-10 16:03:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 744218 | Celldex Therapeutics Inc. | CLDX | In Vitro & In Vivo Diagnostic Substances (2835) | 133191702 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709113 | Sarah Cavanaugh | C/O Celldex Therapeutics, Inc. 53 Frontage Road, Suite 220 Hampton NJ 08827 | Svp Of Corp Affairs & Admin. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-12-08 | 1,857 | $9.02 | 2,265 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-12-08 | 5,466 | $10.38 | 7,731 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-08 | 7,323 | $40.00 | 408 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (Right to Buy) | Disposition | 2021-12-08 | 1,857 | $0.00 | 1,857 | $9.02 |
| Common Stock | Incentive Stock Option (Right to Buy) | Disposition | 2021-12-08 | 5,466 | $0.00 | 5,466 | $10.38 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 11,458 | 2028-06-13 | No | 4 | M | Direct | |
| 78,534 | 2030-06-18 | No | 4 | M | Direct |
Footnotes
- The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
- 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Billionaire Hedge Funds
